Sinopharm Group Stock Sheds 1.6% in Hong Kong

Dow JonesMay 8 16:33

China National Pharmaceutical Group's Taiji has initiated global business development for its investigational biologic drug, Semaglutide.

Taiji Group (600129.SH) announced that Sinopharm Taiji showcased its core biopharmaceutical candidate, semaglutide, at the Canton Fair and officially launched its global business solicitation. Sinopharm Taiji has constructed active pharmaceutical ingredient (API) and drug product manufacturing facilities in compliance with GMP standards in both China and the United States. The API for this drug has completed US DMF registration, enabling a mature global supply capability.

AASTOCKSMay 5 10:29

Sinopharm Group Stock Advances 1.4% in Hong Kong

Dow JonesMay 4 16:33

Sinopharm Group Stock Slips 1.7% in Hong Kong

Dow JonesApr 30 16:33

Sinopharm Accord's First-Quarter Profit Drops as Revenue Slips and Cash Flow Weakens

TipRanksApr 29 18:16

SINOPHARM: ANNOUNCEMENTPRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OFSINOPHARM ACCORD FOR THE FIRST QUARTER ENDED 31 MARCH 2026

HKEXApr 29 17:54 · Announcements